Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2018. Module: SNOMED CT core
Descriptions:
Id | Description | Lang | Type | Status | Case? | Module |
3681519012 | Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
3681520018 | Acetaminophen 300 mg and phenyltoloxamine citrate 20 mg and salicylamide 200 mg oral capsule | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
3681521019 | Paracetamol 300 mg and phenyltoloxamine citrate 20 mg and salicylamide 200 mg oral capsule | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | est un(e) (attribut) | Product containing only paracetamol and phenyltoloxamine and salicylamide in oral dose form (medicinal product form) | true | Inferred relationship | Some | ||
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Has basis of strength substance (attribute) | Salicylamide | true | Inferred relationship | Some | 2 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Has basis of strength substance (attribute) | Phenyltoloxamine citrate | true | Inferred relationship | Some | 1 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Has precise active ingredient | Acetaminophen | true | Inferred relationship | Some | 3 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Has precise active ingredient | Salicylamide | true | Inferred relationship | Some | 2 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Has basis of strength substance (attribute) | Acetaminophen | true | Inferred relationship | Some | 3 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Has precise active ingredient | Phenyltoloxamine citrate | true | Inferred relationship | Some | 1 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | est un(e) (attribut) | Product containing phenyltoloxamine (medicinal product) | false | Inferred relationship | Some | ||
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | est un(e) (attribut) | Acetaminophen compound preparation | false | Inferred relationship | Some | ||
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | a pour principe actif (attribut) | Ethanolamine | false | Inferred relationship | Some | ||
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | a pour principe actif (attribut) | Sedating antihistamine (substance) | false | Inferred relationship | Some | ||
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | a pour principe actif (attribut) | analgésique non opioïde | false | Inferred relationship | Some | ||
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | a pour principe actif (attribut) | Phenyltoloxamine (substance) | false | Inferred relationship | Some | ||
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | est un(e) (attribut) | Acetaminophen + phenyltoloxamine citrate + salicylamide | false | Inferred relationship | Some | ||
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | a pour principe actif (attribut) | Phenyltoloxamine citrate | false | Inferred relationship | Some | ||
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | a pour principe actif (attribut) | Salicylamide | false | Inferred relationship | Some | ||
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | a pour principe actif (attribut) | Acetaminophen | false | Inferred relationship | Some | ||
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | a une forme pharmaceutique (attribut) | Capsule | false | Inferred relationship | Some | ||
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | a pour principe actif (attribut) | Cardiovascular agent (substance) | false | Inferred relationship | Some | ||
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | a une forme pharmaceutique (attribut) | Oral capsule | true | Inferred relationship | Some | ||
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | est un(e) (attribut) | Acetaminophen-containing product in oral dose form | false | Inferred relationship | Some | ||
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | a pour principe actif (attribut) | Acetaminophen | false | Inferred relationship | Some | 1 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Has basis of strength substance (attribute) | Acetaminophen | false | Inferred relationship | Some | 1 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Has presentation strength numerator value (attribute) | 300 (qualifier value) | false | Inferred relationship | Some | 1 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Has presentation strength numerator unit | milligram (qualifier value) | true | Inferred relationship | Some | 1 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Has presentation strength denominator value | un | false | Inferred relationship | Some | 1 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Has presentation strength denominator unit (attribute) | Capsule (unit of presentation) | true | Inferred relationship | Some | 1 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Has presentation strength numerator unit | milligram (qualifier value) | true | Inferred relationship | Some | 2 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Has presentation strength denominator value | un | false | Inferred relationship | Some | 2 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Has presentation strength denominator unit (attribute) | Capsule (unit of presentation) | true | Inferred relationship | Some | 2 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Has presentation strength numerator unit | milligram (qualifier value) | true | Inferred relationship | Some | 3 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Has presentation strength denominator value | un | false | Inferred relationship | Some | 3 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Has presentation strength denominator unit (attribute) | Capsule (unit of presentation) | true | Inferred relationship | Some | 3 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | a pour principe actif (attribut) | Phenyltoloxamine citrate | false | Inferred relationship | Some | 2 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Has basis of strength substance (attribute) | Phenyltoloxamine citrate | false | Inferred relationship | Some | 2 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Has presentation strength numerator value (attribute) | 20 (qualifier value) | false | Inferred relationship | Some | 2 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | a pour principe actif (attribut) | Salicylamide | false | Inferred relationship | Some | 3 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Has basis of strength substance (attribute) | Salicylamide | false | Inferred relationship | Some | 3 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Has presentation strength numerator value (attribute) | 200 (qualifier value) | false | Inferred relationship | Some | 3 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Has precise active ingredient | Salicylamide | false | Inferred relationship | Some | 3 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Has unit of presentation | Capsule (unit of presentation) | true | Inferred relationship | Some | ||
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Has precise active ingredient | Phenyltoloxamine citrate | false | Inferred relationship | Some | 2 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Has precise active ingredient | Acetaminophen | false | Inferred relationship | Some | 1 | |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | est un(e) (attribut) | Acetaminophen- and phenyltoloxamine- and salicylamide-containing product in oral dose form | false | Inferred relationship | Some | ||
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) | Count of base of active ingredient | trois | false | Inferred relationship | Some |
Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets